Established drug given to new indication Ipratropium bromide by exertional laryngeal obstruction (EILO - Exercise Induced Laryngeal Obstruction)[Ipratropium bromide ved anstrengelsesutløst laryngeal obstruksjon (EILO - Exercise Induced Laryngeal Obstruction)]

Trial Profile

Established drug given to new indication Ipratropium bromide by exertional laryngeal obstruction (EILO - Exercise Induced Laryngeal Obstruction)[Ipratropium bromide ved anstrengelsesutløst laryngeal obstruksjon (EILO - Exercise Induced Laryngeal Obstruction)]

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2016

At a glance

  • Drugs Ipratropium bromide (Primary)
  • Indications Laryngospasm
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 May 2016 Planned End Date changed from 4 May 2015 to 4 Feb 2016.
    • 12 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top